您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Atovaquone
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Atovaquone
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Atovaquone图片
包装与价格:
包装价格(元)
10mg电议
50mg电议

产品介绍
Atovaquone 用于治疗或预防肺孢子菌肺炎,弓形虫病, 疟疾和巴贝西虫。

Parasites

B. gibsoni

Preparation method

The solubility of this compound in DMSO is >17.03mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 ℃ for several months.

Reacting condition

0 ~ 3.2 μM

Applications

The ΣFICs against WT B. gibsoni were 0.93, 0.82, 0.83 and 0.96 for Atovaquone and Proguanil at a ratio of 4:1, 3:2, 2:3 and 1:4, respectively. The ΣFICs against Atovaquone-resistant B. gibsoni were 0.88, 0.60, 0.77 and 0.88 at each ratio. The results implied that Atovaquone synergized the effects of Proguanil on WT and Atovaquone-resistant B. gibsoni.

Animal models

Dogs infected with B. gibsoni

Dosage form

17 ~ 25 mg/kg; p.o.

Applications

In B. gibsoni-infected dogs, the combination of Atovaquone and Proguanil alleviated parasitemia. However, all dogs showed relapse of parasitic infection. In addition, some side effects were also observed. Self-limiting vomiting occurred in 2 dogs and hyperphosphatasia occurred in another dog. Mild increases in the alanine aminotransferase levels were confirmed in 2 dogs.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

产品描述

Atovaquone is a medication used to treat or prevent for pneumocystis pneumonia, toxoplasmosis, malaria, and babesia.Target: AntiparasiticAtovaquone (atavaquone) is a chemical compound that belongs to the class of naphthalenes. Atovaquone is a hydroxy-1,4-naphthoquinone, an analog of ubiquinone, with antipneumocystic activity [1]. Atovaquone is an anti-protozoal mitochondrial electron transport inhibitor; Antimalarial; Antipneumocystic, and has also been used to treat toxoplasmosis. It acts by inhibiting the cytochrome bc(1) complex via interactions with the Rieske iron-sulfur protein and cytochrome b in the ubiquinol oxidation pocket [2]. Atovaquone is a unique naphthoquinone with broad-spectrum antiprotozoal activity. It is effective for the treatment and prevention of Pneumocystis carinii pneumonia (PCP), it is effective in combination with proguanil for the treatment and prevention of malaria, and it is effective in combination with azithromycin for the treatment of babesiosis [3].

References:
[1]. Looareesuwan, S., et al., Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg, 1996. 54(1): p. 62-6.
[2]. Kessl, J.J., et al., Molecular basis for atovaquone binding to the cytochrome bc1 complex. J Biol Chem, 2003. 278(33): p. 31312-8.
[3]. Baggish, A.L. and D.R. Hill, Antiparasitic agent atovaquone. Antimicrobial agents and chemotherapy, 2002. 46(5): p. 1163-1173.